The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab

被引：58

作者：

Marty, Michel ^{[1
]}

Pivot, Xavier ^{[2
]}

机构：

[1] St Louis Univ Hosp, Ctr Therapeut Innovat Oncol & Haematol, F-75010 Paris, France

[2] Univ Hosp J Minjoz, Dept Oncol, Besancon, France

来源：

EUROPEAN JOURNAL OF CANCER | 2008年 / 44卷 / 07期

关键词：

angiogenesis; vascular endothelial growth factor (VEGF); breast cancer; bevacizumab; tyrosine kinase inhibitor; monoclonal antibody;

D O I：

10.1016/j.ejca.2008.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：912 / 920

页数：9

共 78 条

[21]

Foekens JA, 2001, CANCER RES, V61, P5407

[22] TUMOR BEHAVIOR IN ISOLATED PERFUSED ORGANS - IN VITRO GROWTH AND METASTASES OF BIOPSY MATERIAL IN RABBIT THYROID AND CANINE INTESTINAL SEGMENT [J].

FOLKMAN, J ;

COLE, P ;

ZIMMERMAN, S .

ANNALS OF SURGERY, 1966, 164 (03) :491-+

[23] Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo [J].

Gabrilovich, D ;

Ishida, T ;

Oyama, T ;

Ran, S ;

Kravtsov, V ;

Nadaf, S ;

Carbone, DP .

BLOOD, 1998, 92 (11) :4150-4166

[24] Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma [J].

Gasparini, G ;

Toi, M ;

Gion, M ;

Verderio, P ;

Dittadi, R ;

Hanatani, M ;

Matsubara, I ;

Vinante, O ;

Bonoldi, E ;

Boracchi, P ;

Gatti, C ;

Suzuki, H ;

Tominaga, T .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (02) :139-147

[25] Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis [J].

Gerwins, P ;

Sköldenberg, E ;

Claesson-Welsh, L .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 34 (03) :185-194

[26] Managing patients treated with bevacizumab combination therapy [J].

Gordon, MS ;

Cunningham, D .

ONCOLOGY, 2005, 69 :25-33

[27] Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance [J].

Gupta, VK ;

Jaskowiak, NT ;

Beckett, MA ;

Mauceri, HJ ;

Grunstein, J ;

Johnson, RS ;

Calvin, DA ;

Nodzenski, E ;

Pejovic, M ;

Kufe, DW ;

Posner, MC ;

Weichselbaum, RR .

CANCER JOURNAL, 2002, 8 (01) :47-54

[28]

HOFFMANNLAROCHE F, DATA FILE

[29] THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY - IDENTIFICATION OF A 4TH MOLECULAR-SPECIES AND CHARACTERIZATION OF ALTERNATIVE SPLICING OF RNA [J].

HOUCK, KA ;

FERRARA, N ;

WINER, J ;

CACHIANES, G ;

LI, B ;

LEUNG, DW .

MOLECULAR ENDOCRINOLOGY, 1991, 5 (12) :1806-1814

[30] HYPOXIA-INDUCED TRANSCRIPTIONAL ACTIVATION AND INCREASED MESSENGER-RNA STABILITY OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN C6 GLIOMA-CELLS [J].

IKEDA, E ;

ACHEN, MG ;

BRIER, G ;

RISAU, W .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (34) :19761-19766

← 1 2 3 4 5 6 7 8 →